5-azacitidine and Thalidomide for patients with Myelodysplastic Syndromes to assess safety and efficacy.
Phase of Trial: Phase I/II
Latest Information Update: 19 May 2017
At a glance
- Drugs Azacitidine (Primary) ; Thalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 18 May 2017 Status changed from active, no longer recruiting to completed.
- 25 Jul 2009 New trial record